• 银川爱尔眼科医院
  • 门诊:周一至周日全天8:00--17:30
  • 0951-3056666




AIER Eye Hospital Group is a leading ophthalmic medical group (eye-care service provider) with domestic and global footprint and high-standard medical care capacity, serving patients across Asia, Europe, and North America. AIER has three public-trading companies listed in China, Europe, and Southeast Asia, respectively (Shenzhen Stock Market: AIER, 300015; Spain BME: CBAV; Singapore SGX: 40T). We have so far established 723 ophthalmic hospitals and centers across the world, including 610 hospitals and centers in mainland China, 7 in Hong Kong, China, 1 in the United States, 93 in Europe, and 12 in Southeast Asia. 


Domestic market is the core business of AIER and international market plays a more and more important role in our global strategy. We are committed to introducing and absorbing the cutting-edge technology and advanced management concepts, as well as to contributing to the evolution of China's ophthalmology market, in a specialized, scaled-up and scientific way. 

AIER has successfully explored the business model in line with China’s national and market condition through continuous practice- the “hierarchical chain”- to fully utilize advantages in talent, technology and management so as to achieve better clinical outcome, to improve service standard and to optimize communication between patients and medical personnel. 


Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment.

Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc.

AIER and the universities are sharing the same goal to build an integrated education and research platform by leveraging the strengths of “Good Company” and “Famous University” through in-depth collaboration in areas of hospital co-management, talent and faculty training, academic development and scientific research, so as to train excellent ophthalmic talents for the community, as well as to contribute our wisdom and power to the evolution of the ophthalmology and vision science in China.


Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide.

“Eight Institutes” refers to Eye Institute, Optometry & Visual Science Institute, Keratoconus Institute, Refractive Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial Workstation, which was established after approval; “Two Bases” refers to Hunan International Optometry Science and Technology Cooperation Base and HOME Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint Laboratory” were jointly established. 


On the 10th Anniversary of listing, AIER took “Innovation Driven and Technology Empowered” as the guideline and proposed three strategic goals. The first goal is to expand the medical service network into vast urban and rural areas, enabling patients to experience convenient and high-quality ophthalmic medical service, implementing the strategy of “Healthy China”. The second goal is to continuously improve ophthalmic medical technology in China and to be recognized as world-level excellence by building up Higher level ophthalmic medical center. The last but not the least goal is to promote advancement of human ophthalmology and visual science through global footprint as well as coordinated development of medicine, education, research, production and investment. 

在十九年的创业发展历程中,爱尔眼科凝聚和培养了一批经验丰富、具有开拓创新精神的管理团队和医术精良、治学严谨的眼科医生团队。截至目前,爱尔眼科医院集团及旗下全球员工总数达50000余人,其中眼科医生及视光师总数(含海外) 9000余人,包括一大批博士生导师、硕士生导师、博士、博士后、留学欧美的学者以及临床经验丰富的医生。

Through the past 19-year growth and expansion, AIER has attracted and cultivated a group of experienced management team with innovative spirit, as well as a team of well-trained ophthalmologists and doctors with excellent medical skills and rigorous scholarship. At present, AIER has more than 50,000 employees worldwide. Among them, 9,000 are ophthalmologists and optometrists (including domestic and overseas), with a big group of doctoral supervisors, master supervisors, doctors, post-doctors, oversea scholars, and even core experts with extensive clinical experiences. 


The growth of AIER always sticks to the original intention and mission of “Enabling everyone, no matter rich or poor, has the right to eye health”. We are committed to the bright future of all human beings, insisting on “patient-oriented” principle, and pursuing the harmonious unity of social responsibility and self-development. By adopting the pioneering “Cross Subsidy Model”, while offering our patients higher-quality ophthalmic medical service, AIER also comprehensively carries out blindness prevention and treatment, devotes to public welfare, helps vulnerable groups, and actively unites all forces from society, promoting the comprehensive development of China’s blindness prevention and even the eye health career of citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China Charity Award” by Chinese Government. Besides, we were also awarded many other honors, such as “China Public Welfare Enterprise Award”, “Best Socially Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER responded positively to the national appeal and took the lead in different public benefit activities such as “The Belt and Road Brightness Campaign” and “Mekong Brightness Campaign”, winning unanimous praise from organizers, aid recipient governments and patients. In this way, AIER has been gradually regarded as a representative of global philanthropy activities. 


AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.



爱尔眼科品牌创立 长沙、成都成立爱尔眼科医院












被国家卫计委评为“消除白内障盲突出贡献单位” 中南大学爱尔眼科学院成立;爱尔眼科研究所成立


获“2014中国年度雇主”奖 爱尔眼视光学院成立


入选“2015年中国最有价值品牌500强” 成功申报国家自然科学基金委员会三项“国家自然科学基金”


开启国际化战略,眼科医疗布局进入中国香港(亚洲医疗、理大护眼) 成立国家“湄公河五国光明行”对外医疗援助项目首批非公医疗执行机构; 获“最具社会责任上市公司”奖 获中华医学会授予“中华医学会优秀白内障手术技能培训基地” 携手国际眼科理事会(ICO),培养国际高端眼科人才


加速国际化战略布局,进入美国、欧洲(美国Wang Vision眼科中心、欧洲巴伐利亚眼科) 开展“一带一路 光明行动”,作为中国民间慈善组织首次走出国门而备受关注; 参与“Clinica Baviera-stop Ceguera”公益慈善活动,帮助消除发展中国家可预防和可治疗的失明; 获“2017年度公益项目奖” 获国家自然科学基金委员会项目和青年科学基金项目资助


获国家民政部颁发第十届“中华慈善奖” 获“2018中国品牌价值500强” 参与“澜湄光明行”,善举和高超的技艺得到国际广泛赞誉 加入世界眼科医院协会 发起全国首个由中国主导,全球近视大数据多中心研究项目 获“2017年中华医学科技进步一等奖”


上市十周年眼科医疗布局进入东南亚(东南亚ISEC眼科集团) “你是我的眼”—角膜移植公益行项目及万人复明工程项目,获中国慈善榜慈善项目奖、获中国慈善榜“十大慈善项目”奖 获得2023年第19届世界近视大会主办权(IMC2023)与武汉大学、暨南大学结成战略合作伙伴


助力国内外新冠疫情防控 为疫情防控捐赠财、物超5300余万元,各类应急支援队伍323个,2000余名医护人员加入防控疫情战线,230位医护人员进入武汉方舱医院等防疫一线; 驰援欧洲、东南亚海外地区医院,提供防疫物资; 获国务院扶贫办评选为“企业精准扶贫专项案例50佳”; 获中国红十字基金会年度“天使·杰出人道奉献奖”; 获向光奖“2020向善企业”称号 与安徽医科大学结成战略合作伙伴


获国家民政部颁发第十一届“中华慈善奖” 与中国科学院计算技术研究所联合启动“智能眼健康设备及大数据平台”; 与天津职业大学共建爱尔视光产业学院; 与天津大学、四川大学、深圳职业技术学院结成战略合作伙伴; “博士后科研工作站”正式揭牌; 建设爱尔国际医学院(本科院校)及附属三甲专科医院